On September 22, 2020 AXIM Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological and COVID-19 research, reported that the United States Patent and Trademark Office (USPTO) has issued the Company a new Notice of Allowance for a patent (Application No. 15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and metastasis (Press release, AXIM Biotechnologies, SEP 22, 2020, View Source;utm_medium=rss&utm_campaign=axim-biotechnologies-receives-notice-of-u-s-patent-allowance-for-proprietary-compounds-and-methods-targeting-tumor-metastasis-through-qsox1 [SID1234565474]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Earlier this year, Sapphire Biotech, a subsidiary of AXIM, announced that Skysong Innovations, LLC, the intellectual property management company for Arizona State University, exclusively licensed Patents, Technical Information and Materials (the "Technology") to Sapphire on behalf of ASU and the Mayo Clinic.
The licensed Technology includes SBI-183, which is covered by this patent. SBI-183 selectively targets QSOX1 and, in animal models, has been found to inhibit tumor growth, invasion and suppress metastasis of tumors by inactivating QSOX1.
"At our core, we are an oncology company dedicated to reducing metastasis in cancer patients around the world. This year, roughly 1.8 million people will be diagnosed with cancer in the U.S. alone and we hope to help as many of those people prolong their life as possible," said AXIM Biotech CEO John W. Huemoeller II. "This patent proves that the oncology research we are doing at AXIM is different from the approach others are taking and we are confident in our choice to do so."
Under this invention, AXIM intends to continue generating and testing analogs of SBI-183 to discover the most biologically active form of the compound. Currently, SPX-1009 has proven itself to be tenfold more potent in suppressing tumor invasion and metastasis in vitro than SBI-183. After further testing, SPX-1009 was shown to suppress invasion of breast, kidney and pancreas tumor cells in 2D and 3D invasion assays at tenfold lower concentrations than the parent compound SBI-183.
"I am enthusiastic about the future of analogs of our lead compound SBI-183. Since QSOX1 is a major player in metastasis, identification of QSOX1 inhibitors that suppress metastasis can be used in combination with other anti-neoplastic drugs to deliver a ‘one-two punch’ against cancer," said Dr. Douglas Lake, Ph.D. and co-founder of Sapphire Biotech.